TY - JOUR
T1 - Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells
T2 - Induction via NF-κB activation mediated by EBV-derived latent membrane protein 1
AU - Thompson, M. P.
AU - Aggarwal, B. B.
AU - Shishodia, S.
AU - Estrov, Z.
AU - Kurzrock, R.
PY - 2003/11
Y1 - 2003/11
N2 - Epstein-Barr virus (EBV)-immortalized lymphoblastoid cells express high levels of lymphotoxin and use this molecule as an autocrine growth factor. We hypothesized that the EBV-derived latent membrane protein 1 (LMP1) mediates lymphotoxin production by inducing NF-κB binding to the lymphotoxin promoter. We assessed lymphotoxin production, LMP1 expression, and NF-κB activation in Z-43 (EBV-positive lymphoblastoid cells), Daudi (EBV-positive Burkitt's cells), and 3A4 (EBV-negative Burkitt's cells containing a stably transfected tetracycline-inducible LMP1 construct). Z-43 cells expressed high levels of LMP1 (immunoblot) and lymphotoxin (ELISA); the EBV-positive Burkitt's lymphoma line Daudi expressed neither LMP1 nor lymphotoxin. Similarly, induction of LMP1 in the 3A4 cells (exposed to tetracycline) was accompanied by a 13-fold increase in lymphotoxin levels (ELISA) as compared to uninduced (LMP1-negative) cells. EMSAs demonstrated high levels of NF-κB activation in Z-43 and tetracycline-induced 3A4 cells, but much lower levels in the uninduced 3A4 cells. Exposure of these cells to Bay 11-7082 (an inhibitor of IκB phosphorylation and, therefore, NF-κB activation) abrogated NF-κB binding and lymphotoxin production in a dose-dependent manner in both Z-43 and 3A4 cells. Therefore, in our model system, autocrine lymphotoxin production is largely driven by NF-κB activation, which is in turn mediated by EBV-derived LMP1 signaling.
AB - Epstein-Barr virus (EBV)-immortalized lymphoblastoid cells express high levels of lymphotoxin and use this molecule as an autocrine growth factor. We hypothesized that the EBV-derived latent membrane protein 1 (LMP1) mediates lymphotoxin production by inducing NF-κB binding to the lymphotoxin promoter. We assessed lymphotoxin production, LMP1 expression, and NF-κB activation in Z-43 (EBV-positive lymphoblastoid cells), Daudi (EBV-positive Burkitt's cells), and 3A4 (EBV-negative Burkitt's cells containing a stably transfected tetracycline-inducible LMP1 construct). Z-43 cells expressed high levels of LMP1 (immunoblot) and lymphotoxin (ELISA); the EBV-positive Burkitt's lymphoma line Daudi expressed neither LMP1 nor lymphotoxin. Similarly, induction of LMP1 in the 3A4 cells (exposed to tetracycline) was accompanied by a 13-fold increase in lymphotoxin levels (ELISA) as compared to uninduced (LMP1-negative) cells. EMSAs demonstrated high levels of NF-κB activation in Z-43 and tetracycline-induced 3A4 cells, but much lower levels in the uninduced 3A4 cells. Exposure of these cells to Bay 11-7082 (an inhibitor of IκB phosphorylation and, therefore, NF-κB activation) abrogated NF-κB binding and lymphotoxin production in a dose-dependent manner in both Z-43 and 3A4 cells. Therefore, in our model system, autocrine lymphotoxin production is largely driven by NF-κB activation, which is in turn mediated by EBV-derived LMP1 signaling.
KW - Deregulation
KW - Growth factor
KW - Molecular mechanism
UR - http://www.scopus.com/inward/record.url?scp=0242643609&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0242643609&partnerID=8YFLogxK
U2 - 10.1038/sj.leu.2403130
DO - 10.1038/sj.leu.2403130
M3 - Article
C2 - 14523478
AN - SCOPUS:0242643609
SN - 0887-6924
VL - 17
SP - 2196
EP - 2201
JO - Leukemia
JF - Leukemia
IS - 11
ER -